Skip to content
drillr.ai
Sign up

HCM

HUTCHMED

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK

$14.18
+0.93%
Ask drillr

  • Sep 29, 2026, 00:18 UTC

    AstraZeneca filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer, as disclosed by HUTCHMED.

    Source:

  • Sep 29, 2026, 00:00 UTC

    HUTCHMED submitted a US New Drug Application for ORPATHYS plus TAGRISSO for MET-driven EGFR-mutated lung cancer after progression on EGFR-TKI therapy.

    Source:

  • Sep 21, 2026, 05:00 UTC

    Chinese biopharma stocks jumped in Hong Kong on Monday, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up more than 6%, HUTCHMED up 3%, Sino Biopharmaceutical up 8%, and the Hang Seng Biotech Index up more than 5%.

    Source:

  • Aug 17, 2026, 07:03 UTC

    AstraZeneca reported positive late-stage trial results for a combination of its lung cancer drugs Tagrisso and Orpathys, potentially paving the way for global approval.

    Source:

  • Jul 2, 2026, 08:30 UTC

    HUTCHMED received NMPA approval for ORPATHYS® for the treatment of gastric cancer patients with MET amplification in China.

    Source: